A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600-mutant solid tumors

Clinton Yam, Xiaowei Xu, Michael A. Davies, Phyllis A. Gimotty, Jennifer J.D. Morrissette, Michael T. Tetzlaff, Khalida M. Wani, Shujing Liu, Wanleng Deng, Meghan Buckley, Jianhua Zhao, Ravi K. Amaravadi, Naomi B. Haas, Ragini R. Kudchadkar, Anna C. Pavlick, Jeffrey A. Sosman, Hussein Tawbi, Luke Walker, Lynn M. Schuchter, Giorgos C. KarakousisTara C. Gangadhar

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600-mutant solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences